Challenges in developing endpoints for type 1 diabetes intervention studies-Reference-Cited by-同舟云学术

Challenges in developing endpoints for type 1 diabetes intervention studies

Published:2009-11 Issue:8 Volume:25 Page:694-704
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab. Res. Rev.

Author:

Cernea Simona,Raz Itamar,Herold Kevan C.,Hirshberg Boaz,Roep Bart O.,Schatz Desmond A.,Fleming G. Alexander,Pozzilli Paolo,Little Randie,Schloot Nanette C.,Leslie R. David G.,Skyler Jay S.,Palmer Jerry P.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference76 articles.

1. ADA Workshop Report: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β-cell function; report of a ADA workshop, 21-22 October 2001;Palmer;Diabetes,2004

2. Immunology of Diabetes Society; Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes;Greenbaum;Diabetes,2003

3. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT);The DCCT Research Group;J Clin Endocrinol Metab,1987

4. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial; a randomized, controlled trial;The Diabetes Control and Complications Trial Research Group;Ann Intern Med,1998

5. β-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial;Steffes;Diabetes Care,2003

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function;Expert Review of Clinical Immunology;2023-11-12

2. Umbilical cord-derived mesenchymal stromal cells preserve endogenous insulin production in type 1 diabetes: a Phase I/II randomised double-blind placebo-controlled trial;Diabetologia;2023-05-24

3. Efficacies of Stem Cell Therapies for Functional Improvement of the β Cell in Patients with Diabetes: A Systematic Review of Controlled Clinical Trials;International Journal of Stem Cells;2019-07-30

4. Novel blood glucose lowering therapies for managing type 1 diabetes in paediatric patients;Expert Opinion on Pharmacotherapy;2018-02-20

5. Remission Phase in Paediatric Type 1 Diabetes: New Understanding and Emerging Biomarkers;Hormone Research in Paediatrics;2017